Population
In vitro models and in vivo models
Comparison
BIBR 277 administered in vitro or in vivo vs Control (baseline or vehicle)
Design
Preclinical
Follow-up
up to 4 days
Authors
Loading...
BIBR 277 shows sustained oral BP reduction in hypertensive rats; leaves open translation to human hypertension trials.
BIBR 277 is an effective and selective AT1 receptor antagonist with sustained antihypertensive activity after oral administration in preclinical models.
Wienen et al. (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: